Abstract. Breast cancer (BC) is a complex disease influenced by environmental and genetic factors. The disease has important genetic and environmental components, most of them are still unknown. An important role of gene polymorphisms related to the risk of developing BC has been reported. However, the results have been controversial. We investigated the association of TSER, MTHFR C677T, p53 codon 72 and MDR1 C3435T gene polymorphisms with breast carcinoma in women from Canary Islands (Spain). Blood samples collected from 135 patients with BC and 304 healthy controls all of them Caucasian, were analyzed through polymerase chain reaction-restriction fragment length polymorphism. Subsequently, a structured questionnaire including patient history and risk factors in relation to BC development was filled out. Allelic frequencies of these genetic variations were: TSER, (2) 0.55 and (3) 0.45 in cases, 0.49 and 0.51 respectively in controls (P=0.240); MTHFR C677T, (C) 0.63 and (T) 0.37 in cases, 0.60 and 0.40 respectively in controls (P=0.568); p53 Arg72Pro, (Arg) 0.74 and (Pro) 0.26 in cases and controls (P=0.910); MDR1 C3435T, (C) 0.52 and (T) 0.48 in cases, 0.55 and 0.45 respectively in controls (P=0.523). We did not observe any gene polymorphism as a risk factor to develop BC. A statistical association was observed between p53 codon 72 polymorphism and family history of breast cancer in both groups, as well as between MDR1 C3435T and smoking habits in cases (P<0.05). Gene polymorphisms vary by regions. The present study contributes to the characterization of the genetic pattern of the Canary population.
Introduction
Breast cancer (BC) is the most common cancer in women. Incidence rates of the disease vary considerably, with the highest rates seen in North America (99.4 per 100,000 women) and Europe (62.3 per 100,000 women) (1) . Canary Islands have one of the highest rates of the disease compared with the rest of the Spanish territory (http://www.gobierno decanarias.org/sanidad/scs/3/3_6/cancer/ppal.jsp). In several ways, Canary population seems to have special characteristics: it is a closed population with less exchange of genetic information (2) , dietary habits are enriched by fat and carbohydrates (Nutrition Survey of Canary, ENCA. http: //www.gobiernodecanarias.org/sanidad/scs/1/plansalud/ enca/ppal_enca.htm) and there is an inadvertent exposure to persistent pesticides (3) . These factors must be related with others, such as genetic factors, to explain the rates of BC in our population. In the last ten years many risk factors for the development of BC (4) have been identified, although the aetiology of the disease is poorly understood. Risk factors that may modulate the development of BC include age, ethnicity, reproductive events, exogenous hormones, lifestyle, bone density and genetic factors (5) . Some molecular markers related to BC have been elucidated as risk factors (6) . Thymidylate synthase (TYMS) is a key enzyme that participates in folate metabolism and catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) in the process of DNA synthesis (7) . This conversion is essential for the provision of thymidine, a nucleotide needed for DNA synthesis and DNA repair (8) . A tandem repeat polymorphism has been identified in the 5'-UTR enhancer region of the TYMS promoter (TSER), the immediate upstream of the ATG codon initiation start site, which contains triple (TSER 3R) or double (TSER 2R) repeats of a 28-bp sequence as well as several rare alleles containing 4, 5 or 9 repeats (9) . In vitro and in vivo studies showed that TYMS expression was TSER genotype-dependent and that the 3R allele was associated with a higher TYMS expression level (9) . TYMS variants are thought to be functionally relevant and are hypothesized to be associated with risk of breast cancer (10) and other cancers (11) .
Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the folate metabolic pathway. It catalyses the conversion of 5,10-methylenetetrahydrofolate (5,10-methylene-THF) to 5-methylenetetrahydrofolate, which is the predominant form of folate in plasma and provides the methyl group for de novo methionine synthesis (12) . C677T is a common single nucleotide polymorphism (SNP) in exon 4 at the folate binding site of the MTHFR gene which results in alanine to valine substitution at codon 222 (13) . Individuals with the MTHFR 677TT genotype have been shown to have only 30% of in vitro MTHFR enzyme activity compared with the wild-type (14) . Reduced activity of the MTHFR, due to C677T polymorphism, influences the general balance between DNA synthesis, repair and methylation processes (15) . MTHFR 677TT has been associated with risk for many different types of cancer, including endometrial, gastric, leukemia, lung, head and neck and colorectal cancers (16) (17) (18) (19) (20) . Nevertheless, several case-control studies investigated the association of MTHFR C677T and BC risk with controversial findings (15) .
Mutations in the p53 gene are the most common genetic alterations in human cancer and they can be found in 20-30% of the sporadic BC (21) . In addition to gene mutations, some polymorphisms in p53 gene have been suggested to play a role in BC (22) . Studies have been focused on a common single-base-repair polymorphism at codon 72, resulting in either a proline (Pro) residue (CCC) or an arginine (Arg) residue (CGC) at this position (23) . The two polymorphic variants have been shown to have structural differences and different biological properties (24, 25) . The Pro-rich domain of p53 has been shown to be an important component in the apoptotic function of p53. Arg72 form of wild-type p53 harbours a greater apoptosis-inducing potential than the Pro72 variant (24) , and may alter the tumour response to systemic chemotherapy by influencing the apoptotic capacity (26) . The association between codon 72 gene polymorphism and cancer risk has been reported in different populations, although results with regards to most cancers remain controversial (23, (27) (28) (29) .
The multidrug resistance gene 1 (MDR1) product P-glycoprotein (Pgp) represents the most widely studied membrane protein of the large mammalian ABC transporter family (30) . Although the physiological role of Pgp is not fully understood, it is conceivable that Pgp may prevent intracellular accumulation of potentially toxic substances and metabolites (31) . Its wide tissue distribution (adrenal gland, breast, placenta, brain, etc.) suggests that Pgp has a fundamental role in normal cellular metabolism (32) . The MDR1 gene is polymorphic and more than 40 SNPs have been identified so far. The C3435T mutation in exon 26 of the MDR1 gene is a silent mutation encoding the amino acid isoleucine. This polymorphism affects the expression and function of the Pgp in many ways (33, 34) . C3435T polymorphism in the MDR1 gene may limit the local detoxification activity in breast tissue and be a risk factor for cancer development and behaviour (35) . Different studies have been associated this polymorphism in MDR1 gene with smoking, high body mass index and risk of BC (35, 36) .
Considering the above background and observations, we studied the local distribution of TSER, MTHFR C677T, p53 codon 72 and MDR1 C3435T gene polymorphisms in BC patients from Gran Canaria (Canary Islands, Spain) looking for genetic risk factors that could be related with other risk factors (e.g., environmental factors), to help to understand the rate of the disease in our population.
Materials and methods
Patients. Between March 2005 and March 2008, a total of 135 patients diagnosed with primary breast cancer at our Service (Medical Oncology Service, Hospital Insular de Gran Canaria, Gran Canaria, Spain) were enrolled in this study. Patients in clinical stages I-IV were included in the study. The diagnosis of the disease was confirmed by histological examinations. All participants were Caucasians of Canary origin. A second group of 304 healthy age-matched women from the same geographical area enrolled in the 'CDC de Canarias' cohort study, was formed as a control group (37) . The Ethics Committee of our Hospital approved the present study and written informed consent was obtained from each participant before biological samples were obtained. All women in this trial filled out a structured questionnaire including patient history and risk factors in relation to BC development. Age, anthropometrical variables expressed by body mass index (BMI kg/m 2 ), smoking habits, reproductive and menstrual history, exposure to estrogens and family history data were collected in cases and controls. For final analysis of disease risk, only women with >1 year of oral contraceptive consumption were used for cancer risk expression. Demographic characteristics of cases and controls are shown in Table IA and B.
Genotyping. Polymorphic sites in TYMS (TSER), MTHFR (C677T), p53 codon 72 (Arg/Pro) and MDR1 (C3435T) were examined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Genomic DNA was extracted from whole blood (5 ml) using a DNA Isolation Kit for mammalian blood (Roche). DNA was then quantified and stored at -20˚C. PCR was performed on each DNA sample using the primer sequences detailed in Table II . The PCR reactions contained 0.2 mM dNTPs (Amersham Pharmacia), 1X PCR buffer (Applied Biosystems), 1.5 mM MgCl 2 (Applied Biosystems), 1 μM forward and reverse primers (EcoGene), 1 U ampliTaq Gold DNA polymerase (Applied Biosystems) and 200 ng DNA in a 20-μl reaction volume. PCR amplification protocol for TSER included 10% of DMSO. For the amplification of the DNA regions containing the polymorphic sites in TSER, the following program was used (38, 39) : an initial denaturation step at 95˚C for 10 min, 40 cycles of 30 sec at 95˚C, 30 sec at 63˚C, 30 sec at 72˚C, and a final extension step of 7 min at 72˚C. The PCR amplification conditions for the polymorphism MTHFR C677T consisted of (39) an initial denaturation step at 95˚C for 10 min, followed by 40 cycles of 1 min at 95˚C, 1 min at 63˚C, 1 min at 72˚C and a final extension step at 72˚C for 7 min. The PCR amplification conditions for the polymorphism at codon 72 in p53 consisted of (26) an initial denaturation step at 94˚C for 2 min, followed by 35 cycles of 30 sec at 94˚C, 45 sec at 60˚C, 30 sec at 72˚C and a final extension step at 72˚C for 10 min. The PCR amplification conditions for the polymorphism in MDR1 C3435T consisted of (36) an initial denaturation step at 94˚C for 2 min, followed by 35 cycles of 30 sec at 94˚C, 30 sec at 60˚C, 30 sec at 72˚C and a final extension step at 72˚C for 4 min. Except for TSER, the amplified fragments were digested with the appropriate restriction endonucleases (New England BioLabs) listed in Table II . After incubation at the optimal temperature, 20 μl of digested product was analyzed by gel electrophoresis on a 2-3% low melting agarose gel and visualized under ultraviolet light in a ChemiDoc System (Bio-Rad) after staining with ethidium bromide (Pierce). Electrophoresis identification of the alleles by their PCR product length is shown in Fig. 1 .
Statistical analysis. The difference in allele or genotype frequencies between controls and BC patients was determined using the ¯2 test, as well for determination of the deviation from the Hardy-Weinberg equilibrium. A binary logistic regression model was used to calculate the odds ratio (OR) and the corresponding 95% confidence interval (CI) to set the association between the polymorphisms and cancer risk. T-test was used to explore the association between continuous variables. ¯2 test was used in the case of categorical ONCOLOGY REPORTS 22: 1425 -1433 Table I-A. Demographic characteristics of cancer patients and controls. 
Family history of breast cancer in first degree relatives. ND, non-determined.
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variables. All tests were two-sided and differences were considered significant at p<0.05. All analysis were performed with SPSS for Windows (version 15.0; SPSS, Chicago, IL), in April 2009.
Results
The study population consisted of 135 women with histologically confirmed breast carcinoma with an age range from Table II . Technical details of PCR-RFLP analysis. Table IA and B. There was a significant difference between menopausal frequencies in cases compared with controls (¯2 test, P<0.001). Mean age at first labor was 25.88 and 23.59 years in cases and controls, respectively, with a significant difference between means (t-test, P<0.001). In our study population, patients with BC gave birth >2 years later than control women. There was no significant difference in relation to lactation, although the mean of months of lactation was higher in cases (8.99) compared with controls (6.52) (ttest, P=0.042). TSER, MTHFR C677T, p53 Arg72Pro and MDR1 C3435T alleles and genotype frequencies were estimated for control group and patients with BC in the current study. More than 95% of the polymorphism determinations were successful. Genotype and allelic frequencies are shown in Table III . No significant differences were observed in any case, and there were no statistical changes of genotype distribution of polymorphisms in cases and controls when stratified by age (<50 vs. 50-59 vs. >60; <50 vs. ≥50 years) or by BMI (≤25 vs. 25.1-30 vs. >30) (data not shown). The genotype distributions among cases and controls were in Hardy-Weinberg equilibrium (P=NS). We did not observe incremented risk of BC in relation with any genotype of the genes under study (P=NS, binary logistic regression model used). We observed a significant association between p53 Arg72Pro genotype and family history of BC in control group (¯2 test, P=0.024). Allele Pro was present in 36.5% of healthy people with family history of the illness compared with the 24.5% of allelic frequency detected in people with non-familial history (¯2 test, P=0.096). The same pattern was observed in the group of patients with BC (P=0.031). Allele Pro was present in 42.9% of patients with family history compared with the 24.1% of patients with non-family history of BC (¯2 test, P=0.132). These data are shown in Table IV . ONCOLOGY REPORTS 22: 1425 -1433 Table III. Genotype and allelic frequencies of gene polymorphisms in this study.
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Related to this gene, we made a comparison of codon 72 polymorphism in healthy women from different populations of the world (Table V) (23) . We found significant differences between genotype distribution in our population compared with people from China, Greece, Nigeria, Tunisia and Israel. On the other hand, our population seems to have a similar genotype distribution of p53 Arg72Pro to healthy women from Peru, Portugal, Sweden, USA, Germany, Italy and Russia. Regarding MDR1 C3435T, we observed a significant association between this gene polymorphism and smoking, but only in patients with BC (P=0.038). In patients, a slight reduction of allele T was detected in non-smokers compared with smokers (47.3 and 50%, respectively). In any case, this change in allelic distribution was statistically significant (Table IV) . No significant association was observed between MDR1 and smoking in the control group (data not shown).
Discussion
In the present study we explored the role of TSER, MTHFR C677T, p53 Arg72Pro and MDR1 C3435T gene polymorphisms in Canary population, looking for genetic findings that could help to understand the specific characteristics related to breast cancer observed in our population. All the gene polymorphisms were selected in order to investigate the relation with breast cancer risk. TSER is a single tandem repeat polymorphism in the 5'-UTR enhancer region of the thymidylate synthase promoter (TYSM). The role of TSER in the response to fluoropyrimidine-based chemotherapy has been reported and accepted (40) . However, its implication in cancer as a risk factor is actually not clear. Ko et al observed an incremented risk of cholangiocarcinoma in 47 carriers of TSER 2R (+) in combination with MTHFR 677CC compared with 204 healthy controls in a Korean population (11) . Related to breast cancer, a case-control study was made in 432 patients and 473 free of cancer controls from China (10) . Different gene polymorphisms in TYMS were determined. Authors suggested that the TS3'-UTR del6 polymorphism may play a role in the etiology of breast cancer. No association was observed in relation with TSER. Genetic polymorphisms vary between ethnic groups. In the study of Zhai et al (10) , the frequencies of TSER 3R/3R, 2R/3R and 2R/2R genotypes were 64.5, 30.2 and 5.3%, respectively, among 473 control subjects, which were significantly different from those among the 283 controls presented in the present study (P<0.0001). The genotype distribution is quite different between Chinese and Canary populations. Despite this, our findings do not contradict the results of this large study, because we did not observe any relation between breast cancer risk and TSER. In the other hand, genotype frequencies of TSER in our study was similar to other Caucasian populations (¯2 test, P=NS) (41, 42) .
The role of MTHFR C677T gene polymorphism in breast cancer risk is very controversial. Allele T seems to be involved in cancer risk. There are some studies in favor of this argument (43), most of them in people from Turkey and oriental countries (44, 45) . This hypothesis is refuted by different authors in different populations (46, 47) . Moreover, there are studies that support a possible benefit of this polymorphism in the prevention of breast cancer (48) . Several meta-analysis indicate that this gene polymorphism is a possible modifier of breast cancer risk, specially in association with other risk factors such as estrogen exposure in premenopausal women. Furthermore, there is some evidence that high folate intake may counterbalance the effect of this SNP in increasing breast cancer risk (15, 49) . We did not observe any association between MTHFR C677T gene polymorphism and breast cancer risk when cases and control subjects were stratified by menopausal status, even by oral contraceptive exposure. Notwithstanding, a borderline significance was observed in allele distribution in premenopausal women (¯2 test, P=0.074). Allele T was less frequent in patients with breast cancer compared with controls (29 and 42%, respectively). The same pattern in T allele frequency was observed in other publications (48, 50) . No significant increment in cancer risk 
was detected related to this finding. Genotype and allele distributions change depending on the population studied. This is why we compared genotype and allele frequencies from our study with others (15). We did not observe differences comparing with people from UK, USA, Austria, Germany or Italy (¯2 test, P=NS). Nevertheless, a significant difference was observed between our population compared with Turkish and white non-Hispanic people from USA (¯2 test, P<0.05). Sample size, experimental design and patient selection, end-points considered (folate intake) and intrinsic characteristics of each population could help to explain these findings.
The association between p53 codon 72 gene polymorphism and cancer risk has been reported in different populations, although results with regard to most cancer remain incomplete (27) (28) (29) . In our population, we did not observed any differences in genotype and allele distributions between cases and controls, and no increment in breast cancer risk was detected. Studies that support the hypothesis related to this polymorphism as a cancer risk observed a relative frequency of the Arg allele higher in breast cancer patients (23) . This finding was not reproduced in the present study. These contradictory results may be attributed to the ethnic differences, chance deviations, or publication bias toward 'positive' findings. There are considerable variations in the distribution of the codon 72 genotypes in several populations. This SNP seems to be maintained by natural selection influenced by environmental factors, such as the degree of exposure to sunlight UV-B component (51) . Population-based studies indicate that the Arg allele is most prevalent in individuals with light complexion, with a clear decline in the prevalence of Pro allele with increasing north latitude (51) . We compared the genotype and allele distribution of our population with other ones, concluding significant differences with people from China, Greece, Nigeria, Tunisia and Israel. Unexpected, because the Canary population has a light complex, the genotype distribution of this gene polymorphism was similar to other populations from Europe, USA and Peru, indicating that genotype distribution in our region has it own characteristics. We observed a significant association between p53 Arg72Pro genotype and family history of BC in cases and controls. This SNP seems to be relevant in the modulation of apoptotic capacity of cells, with Pro allele reducing apoptosis potential (24) . Because this association was observed in cases and controls in the same pattern (Table IV) , this finding may be explained, at least in part, by the natural selection and genetic inheritance of p53 Arg72Pro gene polymorphism.
MDR1 C3435T has been involved in susceptibility and prognosis of some cancers with more or less positive association. The results varied in level of statistical significance and role of genotype consequence. Whereas the T/T form was in majority associated with higher risk of disease origin, the carriers of C/C genotype were supposed to have a worse prognosis (35) . We did not observe significant differences in this gene polymorphism between patients with breast cancer compared with controls. These findings are in contrast with other studies, although the literature on the 'functional' effects of SNPs in the MDR1 gene is replete with contradictory findings (52) . Turgut et al demonstrated a 1.5-fold increased risk for development of breast cancer in T allele carriers, in a study with 57 patients and 50 healthy subjects in a Turkish population (36) . In the present study, T allele in cases was slightly higher than in controls, but this finding was not significant. Sample size and intrinsic characteristics of each population could explain this result. The human multidrug resistance gene 1 encodes a plasma membrane Pglycoprotein (Pgp) that functions as the transmembrane efflux pump for various structurally unrelated anticancer agents and toxins. Functional polymorphism C3435T in the MDR1 gene alters the detoxification protective function of Pgp in breast tissue cells exposed to environmental carcinogens in tobacco smoke. This SNP occurs in high incidence among women with breast carcinoma where C allele carriers have increased risk of developing cancer when exposed to toxic substances (35) . No significant differences were observed in genotype and allelic frequencies between this publication and the present study. A significant association was detected between MDR1 C3435T genotype frequencies and smoking in cases. T allele was present in high frequency in smoker patients than in non-smokers, but this slight increase in T allele distribution was not significant. No statistical increase in breast cancer risk was detected. It was reported that C/T and T/T carriers have low levels of Pgp expression, provoking an abnormal accumulation of harmful substances into the cells with subsequent cell damage (53) . The meaning of this association in our population should be explored in detail.
In conclusion, TSER, MTHFR C677T, p53 Arg72Pro and MDR1 C3435T gene polymorphisms were determined in 135 patients with primary breast cancer and in 304 healthy controls from the Canary Islands. No significant differences were observed in genotype and allele frequencies between case and control groups, and no breast cancer risk factor was observed related to these polymorphisms. A statistical association was seen between p53 codon 72 gene polymorphism and family history of breast cancer in both groups, as well as between MDR1 C3435T gene polymorphism and smoking habits in cases (35) . We introduced new data that could help to characterize the Canary population. Further experiments are needed to understand the incidence of breast cancer in our region.
